Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacturing of albumin and immunoglobulins from human plasma

Biotechnology and Bioprocess Engineering

Volumn 6, Issue 1, 2001, Pages 25-30

  Kim, In Seop ^a   Eo, Ho Gueon ^a   Park, Chan Woo ^a   Chang, Chong E ^a   Lee, Soungmin ^a  

^a Green Cross Company   (South Korea)

Author keywords

Albumin; Cold ethanol fractionation; Human immunodeficiency virus; Immunoglobulins; Log reduction value; Pasteurization

Indexed keywords

EID: 33644757394     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02942246     Document Type: Article

References (22)

1. Cohn, E. J., L. E. Strong, W. L. Hughes Jr, D. J. Mulford, J. N. Ashworth, M. Melin, and H. L. Taylor (1946) Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the proteins and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 68: 459-475.
2. Horowitz, B. (1990) Blood protein derivative viral safety: observations and analysis. Yale J. Med. 63: 361-369.
3. Mosley J. W. and J. Rakela (1999) Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044.
4. Berkman S. A. (1988) Infectious complications of blood transfusion. Blood Rev. 2: 206-210.
5. Schilt, U. (1989) Overview of viruses relevant to blood transfusion. Curr. Stud. Hematol. Blood Transfus. 56: 1-8.
6. Cuthbertson, B., K. G. Reid, and P. R. Foster (1991) Viral contamination of human plasma and procedures for preventing virus transmission by plasma products, pp. 385-435. In: J. R. Harris (eds.). Blood separation and plasma fractionation. Wiley-Liss., NY, USA.
7. Will, R. G., J. W. Ironside, M. Zeidler, S. N. Cousens, K. Estibeiro, A. Alperovitch, S. Poster, M. Pocchiari, A. Hofman, and P. G. Smith (1996) A new varient of Creutzfeldt-Jakob-Disease in the UK. Lancet 347: 921-925.
8. Erstad, B. L. (1996) Viral infectivity of albumin and plasma protein fraction. Pharmacotherapy 16: 996-1001.
9. Roberts, P. (1996) Virus safety of plasma products. Rev. Med. Virol. 6: 25-38.
10. Federal Health Office and Paul Ehrlich Institute Federal Office for Sera and Vaccines (1994) Notice on the registration of drugs: requirements for validation studies to demonstrate the virus safety of drugs derived from human blood or plasma. Bundesanzeiger 84: 4742-4744.
11. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95).
12. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on plasma derived medicinal products (CPMP/BWP/269/95 rev2).
13. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on quality of biotechnology products: viral safety evaluation of biotechnology products derived from cell Lines of human or animal origin (CPMP/ICH/295/95).
14. International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Availability. Federal Resister 63(185): 51074-51084.
15. Oncley J. L., M. Melin, D. A. Richert, J. W. Cameron, and P. M. Jr. Gross (1949) The separation of the antibodies, isoaggulitinins, prothrombin, plasminogen and β-lipoprotein into subfractions of human plasma. J. Am. Chem. Soc. 71: 541-550.
16. Kärber, J. (1931) Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Path. Pharmak. 162: 480-483.
17. Morgenthaler, J. J. (1989) Inactivation of viruses and safety of stable plasma products. Beitr. Infusionsther. 24: 33-39.
18. Menache, D. and D. L. Aronson (1985) Measures to inactivate viral contaminants of pooled plasma products. Prog. Clin. Biol. Res. 182: 407-423.
19. Heimburger, N. and H. E. Karges (1989) Strategies to produce virus-safe blood derivatives. Curt Stud. Hematol. Blood Transfus. 56: 23-33.
20. Heldebrant, C. M., E. D. Gomperts, C. K. Kasper, J. S. McDougal, A. E. Friedman, D. S. Hwang, E. Muchmore, S. Jordan, R. Miller, E. Sergis-Da-Venport, and W. Lam (1985) Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates. Transfusion 25: 510-515.
21. Nowak, T., J.-P. Gregersen, U. Klockmann, L. B. Cummins, and J. Hilfenhaus (1992) Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J. Med. Virol. 36: 209-216.
22. Uemura, Y., Y. H. J. Yang, C. M. Heldebrant, K. Takechi, and K. Yokoyama (1994) Inactivation and elemination of viruses during preparation of human intravenous immunoglobulin. Vox Sang. 67: 246-254.